"The completion of enrollment of our diSArm study is a significant milestone in the development of AP-SA02, moving us one step closer to introducing an effective new treatment option to patients ...
Armata Pharmaceuticals (ARMP) announced “encouraging” topline results from its Phase 2 trial evaluating AP-PA02, a novel, inhaled multi-phage therapeutic for the treatment of chronic pulmonary ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback